Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer
NCT07092254 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 760
Last updated 2026-02-20
Summary
This transnational noninterventional study aims to gather real-world evidence on locally recurrent inoperable (hereafter referred to as advanced) or metastatic TNBC (a/m TNBC) biomarker testing, treatment patterns by line of therapy, and outcomes to contextualize findings of TROPION-Breast02 and TROPION-Breast05 in selected settings outside the United States (US), including Canada, the United Kingdom (UK), France, and Spain.
Conditions
Interventions
- DRUG
-
No drug
No study drug will be administered in this non-interventional study.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Director · Daiichi Sankyo
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-09-01
- Primary Completion
- 2025-11-28
- Completion
- 2026-06-12
Countries
- United States
Study Locations
More Related Trials
-
Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
NCT03838367 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Biomarkers of Efficacy and Tolerability of Sacituzumab-Govitecan in the Treatment of Patients With Triple-negative Breast Cancer in the Metastatic Phase: Prospective Multicenter Real-world Study
NCT06240195 ·Status: RECRUITING
-
Decitabine Plus Carboplatin in the Treatment of Metastatic TNBC
NCT03295552 ·Status: TERMINATED ·Phase: PHASE2
-
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer
NCT01151449 ·Status: TERMINATED ·Phase: PHASE2
-
Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
NCT02422498 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study on Bisphosphonates Targeting Triple-negative Breast Cancer
NCT04045522 ·Status: UNKNOWN
-
Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
NCT05255666 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer
NCT04690855 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer
NCT01492556 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
NCT01881230 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature
NCT02641847 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)
NCT06618014 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
NCT05104866 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
NCT02768701 ·Status: COMPLETED ·Phase: PHASE2
-
Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer
NCT07019337 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer
NCT01732276 ·Status: UNKNOWN ·Phase: PHASE2
-
Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
NCT04249167 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer
NCT03106077 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study
NCT07251868 ·Status: RECRUITING
-
Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer
NCT04452370 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer
NCT04461600 ·Status: TERMINATED ·Phase: PHASE2
-
Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.
NCT05181462 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis
NCT07263425 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
NCT03316794 ·Status: TERMINATED ·Phase: PHASE1
-
Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
NCT06682195 ·Status: RECRUITING ·Phase: PHASE2